Showing results (71-80 of 110) with videos related to
Sort By:
Pageof 11
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapyMelissa G Lechner, Saman S Karimi, Keegan Barry-Holson, et al.Urology|February 5, 2013
Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1Sarah M Russell, Melissa G Lechner, Anusuya Mokashi, et al.Diagnostic Pathology|July 6, 2020
Liver metastases from pituitary carcinomas mimicking visceral well-differentiated neuroendocrine tumors: a series of four casesElise R Venable, Sarah E Kerr, M Beatriz S Lopes, et al.The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective StudyAshish V Chintakuntlawar, Kandelaria M Rumilla, Carin Y Smith, et al.Clinical Breast Cancer|January 14, 2022
Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort StudyNikhita Kathuria-Prakash, Lauren Antrim, Nicholas Hornstein, et al.Cancer Research|June 3, 2009
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1Julio C Ricarte-Filho, Mabel Ryder, Dhananjay A Chitale, et al.Oral Oncology|July 2, 2011
USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristicsSarah M Russell, Melissa G Lechner, Lucy Gong, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A Thompson, Bryan J Schneider, Julie Brahmer, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 25, 2025
Outcomes of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and ParagangliomaGokce Belge Bilgin, Brian J Burkett, Cem Bilgin, et al.Clinical & Translational Immunology|May 10, 2021
Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitorsSvetlana Bornschlegl, Michael P Gustafson, Danae A Delivanis, et al.Pageof 11